CoChat

Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial

Open access
Mann, Douglas L., Givertz, Michael M., Vader, Justin M., Starling, Randall C., Shah, Palak, McNulty, Steven E., Anstrom, Kevin J., Margulies, Kenneth B., Kiernan, Michael S., Mahr, Claudius, Gupta, Divya, Redfield, Margaret M., Lala, Anuradha, Lewis, Gregory D., DeVore, Adam D., Desvigne-Nickens, Patrice, Hernandez, Adrian F., Braunwald, Eugene, LIFE Investigators, Mohammed, Selma F., Birru, Hellina, Aboye, Etsubdink, Lam, Phillip H., Escobar, Nicole, Fink, Maria, Cappola, Thomas P., Sheaffer, Wendy, Reilly, Bonitta, Ferree, Jenny, Ravichandran, Ashwin K., Ciezkowski, Gina, Herrera, Glenda, Mehta, Hirsch S., DeLucca, Rosemarie, Doddamani, Sanjay, Kanwar, Manreet, Thomas, Brooke, Machen, Laurie, Kim, January, Christina, Athas, Lampert, Brent C., Fontenelle, Cindy, Eiswirth, Clement C., Williams, Julie, Rock, Darlene, Egnaczyk, Gregory F., Rentas-Sherman, Enya, Barr, Deborah, Bhimaraj, Arvind, Damato, Adrianna, Calayo, Christine, Herre, John M., Lindenfeld, Joann, Carroll, Amanda, Gordon, Mary, Keebler, Mary E., Setliff, Bandaa, Gulati, Sanjeev K., Winkler, Krystal, Curtin, Laura, Ohmart, Carly, Halvorson, John, Mudd, James O., Camacho, S. Albert, Palardy, Maryse, Shah, Neha, Picardi, Kristina, Krishnamoorthy, Arun, Maximin, Adrienne, Horstmanshof, Douglas A., Seiler, Beverly, Xu, Zi J., Mersola, Savannah, Kransdorf, Evan P., Tang, Wilson, Fonk, Teresa, Gorodeski, Eiran Z., Oliveira, Guilherme H., Semenec, Terrence, Norton, Nadine, Nichols, Julie, Leo, Peter, Dunlap, Mark E., Felker, G. Michael, Taylor, Lacey, Sheehan, Mary, Levine, Sharon, Cocca-Spofford, Diane, Brooks, Liana, Cunningham, Thomas, Acker, Nancy, Milbrandt, Susan, Gatzke, Janet, Davila-Roman, Victor G., Dirks, Anne, Bult, Karen, Weber, Elizabeth, Lesko, Mary, Mikhalkova, Deana, Fitzgerald, Kathleen, Whellan, David J., Wever-Pinzon, Omar, Gutierrez, Jonathan, Goldsborough, Yavette, Gilotra, Nisha A., Caikauskaite, Indre, Skopicki, Hal A., Huggins, Gordon S., Yuen, Nathan, Haynes, Abbey, Katie, Carr, Snell, Gail, Smith, Andrew L., Walker, Brandon, Johnson, Jovita, Henderson, Simmone, Pauwaa, Sunil, Bhat, Geetha, Gagliardi, Ann · 2022 · JAMA Cardiology
Cited by 178

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Importance: The use of sacubitril/valsartan is not endorsed by practice guidelines for use in patients with New York Heart Association class IV heart failure with a reduced ejection fraction because of limited clinical experience in this population. Objective: To compare treatment with sacubitril/valsartan treatment with valsartan in patients with advanced heart failure and a reduced ejection fraction and recent New York Heart Association class IV symptoms. Design, Setting, and Participants: A double-blind randomized clinical trial was conducted; a total of 335 patients with advanced heart failure were included. The trial began on March 2, 2017, and was stopped early on March 23, 2020, owing to COVID-19 risk. Intervention: Patients were randomized to receive sacubitril/valsartan (target dose, 200 mg twice daily) or valsartan (target dose, 160 mg twice daily) in addition to recommended therapy. Main Outcomes and Measures: The area under the curve (AUC) for the ratio of N-terminal pro-brain natriuretic peptide (NT-proBNP) compared with baseline measured through 24 weeks of therapy. Results: Of the 335 patients included in the analysis, 245 were men (73%); mean (SD) age was 59.4 (13.5) years. Seventy-two eligible patients (18%) were not able to tolerate sacubitril/valsartan, 100 mg/d, during the short run-in period, and 49 patients (29%) discontinued sacubitril/valsartan during the 24 weeks of the trial. The median NT-proBNP AUC for the valsartan treatment arm (n = 168) was 1.19 (IQR, 0.91-1.64), whereas the AUC for the sacubitril/valsartan treatment arm (n = 167) was 1.08 (IQR, 0.75-1.60). The estimated ratio of change in the NT-proBNP AUC was 0.95 (95% CI 0.84-1.08; P = .45). Compared with valsartan, treatment with sacubitril/valsartan did not improve the clinical composite of number of days alive, out of hospital, and free from heart failure events. Aside from a statistically significant increase in non-life-threatening hyperkalemia in the sacubitril/valsartan arm (28 [17%] vs 15 [9%]; P = .04), there were no observed safety concerns. Conclusions and Relevance: The findings of this trial showed that, in patients with chronic advanced heart failure with a reduced ejection fraction, there was no statistically significant difference between sacubitril/valsartan and valsartan with respect to reducing NT-proBNP levels. Trial Registration: ClinicalTrials.gov Identifier: NCT02816736.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamacardio.2021.4567

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 178

Metadata

Authors
Mann, D. L., Givertz, M. M., Vader, J. M., Starling, R. C., Shah, P., McNulty, S. E., Anstrom, K. J., Margulies, K. B., Kiernan, M. S., Mahr, C., Gupta, D., Redfield, M. M., Lala, A., Lewis, G. D., DeVore, A. D., Desvigne-Nickens, P., Hernandez, A. F., Braunwald, E., LIFE Investigators, Mohammed, S. F., Birru, H., Aboye, E., Lam, P. H., Escobar, N., Fink, M., Cappola, T. P., Sheaffer, W., Reilly, B., Ferree, J., Ravichandran, A. K., Ciezkowski, G., Herrera, G., Mehta, H. S., DeLucca, R., Doddamani, S., Kanwar, M., Thomas, B., Machen, L., Kim, J., Christina, A., Lampert, B. C., Fontenelle, C., Eiswirth, C. C., Williams, J., Rock, D., Egnaczyk, G. F., Rentas-Sherman, E., Barr, D., Bhimaraj, A., Damato, A., Calayo, C., Herre, J. M., Lindenfeld, J., Carroll, A., Gordon, M., Keebler, M. E., Setliff, B., Gulati, S. K., Winkler, K., Curtin, L., Ohmart, C., Halvorson, J., Mudd, J. O., Camacho, S. A., Palardy, M., Shah, N., Picardi, K., Krishnamoorthy, A., Maximin, A., Horstmanshof, D. A., Seiler, B., Xu, Z. J., Mersola, S., Kransdorf, E. P., Tang, W., Fonk, T., Gorodeski, E. Z., Oliveira, G. H., Semenec, T., Norton, N., Nichols, J., Leo, P., Dunlap, M. E., Felker, G. M., Taylor, L., Sheehan, M., Levine, S., Cocca-Spofford, D., Brooks, L., Cunningham, T., Acker, N., Milbrandt, S., Gatzke, J., Davila-Roman, V. G., Dirks, A., Bult, K., Weber, E., Lesko, M., Mikhalkova, D., Fitzgerald, K., Whellan, D. J., Wever-Pinzon, O., Gutierrez, J., Goldsborough, Y., Gilotra, N. A., Caikauskaite, I., Skopicki, H. A., Huggins, G. S., Yuen, N., Haynes, A., Katie, C., Snell, G., Smith, A. L., Walker, B., Johnson, J., Henderson, S., Pauwaa, S., Bhat, G., & Gagliardi, A.
Venue
JAMA Cardiology
Published
2022-01-01
Volume
7
Issue
1
Pages
17
ISSN
2380-6583 (ISSN-L)
OpenAlex
W3208470283
Cited by
178
References
6
FWCI
18.02
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jamacardio.2021.4567
The paper
Mann, D. L., Givertz, M. M., Vader, J. M., Starling, R. C., Shah, P., McNulty, S. E., Anstrom, K. J., Margulies, K. B., Kiernan, M. S., Mahr, C., Gupta, D., Redfield, M. M., Lala, A., Lewis, G. D., DeVore, A. D., Desvigne-Nickens, P., Hernandez, A. F., Braunwald, E., LIFE Investigators, . . . Gagliardi, A. (2022). Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA Cardiology. https://doi.org/10.1001/jamacardio.2021.4567

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.